SPECT and PET in neurology;SPECT y PET en neurología

Neurologia

Volumn 21, Issue 5, 2006, Pages 219-225

  Masdeu, José C ^a,b   Arbizu, J ^a   Toledo, J ^a   Valero, M ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Brain tumor; Dementia; Epilepsy; Parkinson's disease; PET; SPECT; Stroke

Indexed keywords

DOPAMINE;

BRAIN EDEMA; BRAIN INFARCTION; BRAIN TUMOR; CLINICAL PRACTICE; DEMENTIA; FOCAL EPILEPSY; HUMAN; NEUROIMAGING; NEUROLOGY; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STROKE; SUBARACHNOID HEMORRHAGE;

BRAIN DISEASES; BRAIN NEOPLASMS; DEMENTIA; DIAGNOSTIC TECHNIQUES, NEUROLOGICAL; EPILEPSY; HUMANS; MOVEMENT DISORDERS; NEUROLOGY; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 33745959603     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Catafau AM. Brain SPECT in clinical practice. Part I: perfusion. J Nucl Med 2001;42:259-71.
2. Devous MD. Single-photon emission computed tomography in neurotherapeutics. NeuroRx 2005;2:237-49.
3. Magistretti PJ, Pellerin L, Rothman DL, Shulman RG. Energy on demand. Science 1999;283:496-7.
4. Comar D, Cartron J, Maziere M, Marazano C. Labelling and metabolism of methionine-methyl-11 C. Eur J Nucl Med 1976;1:11-4.
5. Masdeu JC. Imaging of stroke with SPECT. En: Babikian V, Wechsler L, Higashida RT, editores. Imaging cerebrovascular disease. Boston: Butterworth-Heinemann, 2003; p. 131-44.
6. Barthel H, Hesse S, Dannenberg C. Prospective value of perfusion and X-ray attenuation imaging with single-photon emission and transmission computed tomography in acute cerebral ischemia. Stroke 2001;32:1588-97.
7. Rieck H, Adelwohrer C, Lungenschmid K, Deisenhammer E. Discordance of technetium-99m-HMPAO and technetium-99m-ECD SPECT in herpes simplex encephalitis. J Nucl Med 1998;39:1508-10.
8. Álvarez-Linera J, Benito-León J, Escribano J, Rey G. Predicting the histopathological grade of cerebral gliomas using high b-value diffusion-weighted MR imaging. Neurology 2006;66(Suppl. 2):A335.
9. Torii K, Tsuyuguchi N, Kawabe J, Sunada I, Hara M, Shiomi S. Correlation of amino-acid uptake using methionine PET and histological classifications in various gliomas. Ann Nucl Med 2005;19:677-83.
10. Kim S, Chung JK, Im SH. 11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imag 2005;32:52-9.
11. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 1993;34:414-9.
12. Fulham MJ, Melisi JW, Nishimiya J, Dwyer AJ, Di Chiro G. Neuroimaging of juvenile pilocytic astrocytomas: an enigma. Radiology 1993;189:221-5.
13. Sasaki M, Ichiya Y, Kuwabara Y. Ringlike uptake of [18F]FDG in brain abscess: a PET study. J Comput Assist Tomogr 1990;14:486-7.
14. Dethy S, Goldman S, Blecic S, Luxen A, Levivier M, Hildebrand J. Carbon-11-methionine and fluorine-18-FDG PET study in brain hematoma. J Nucl Med 1994;35:1162-6.
15. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33:1972-80.
16. Levivier M, Goldman S, Pirotte B. Diagnostic yield of stereotactic brain biopsy guided by positron emission tomography with [18F]fluorodeoxyglucose. J Neurosurg 1995;82:445-52.
17. Janus TJ, Kim EE, Tilbury R, Bruner JM, Yung WK. Use of [18F] fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. Ann Neurol 1993;33:540-8.
18. Ishikawa M, Kikuchi H, Miyatake S, Oda Y, Yonekura Y, Nishizawa S. Glucose consumption in recurrent gliomas. Neurosurgery 1993;33:28-33.
19. Ogawa T, Inugami A, Hatazawa J. Clinical positron emission tomography for brain tumors: comparison of fludeoxyglucose F 18 and L-methyl-11C-methionine. AJNR Am J Neuroradiol 1996;17:345-53.
20. Setoain X, Carreño M, Bargalló N, Rumià J, Donaire A, Fuster D, et al. ¿Es útil el SPECT interictal en la epilepsia del lóbulo temporal? Neurología 2006;21:226-31.
21. Cascino GD, So EL, Buchhalter JR, Mullan BP. The current place of single photon emission computed tomography in epilepsy evaluations. Neuroimaging Clin N Am 2004;14:553-61.
22. Juhasz C, Chugani HT. Imaging the epileptic brain with positron emission tomography. Neuroimaging Clin N Am 2003;13:705-16.
23. Lee SK, Lee SY, Kim KK, Hong KS, Lee DS, Chung CK. Surgical outcome and prognostic factors of cryptogenic neocortical epilepsy. Ann Neurol 2005;58:525-32.
24. Carnero-Pardo C. Systematic review of the value of positron emission tomography in the diagnosis of Alzheimer's disease. Rev Neurol 2003;37:860-70.
25. Knopman DS, DeKosky ST, Cummings JL Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1143-53.
26. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1133-42.
27. Kantarci K, Jack CR, Jr. Neuroimaging in Alzheimer disease: an evidence-based review. Neuroimaging Clin N Am 2003;13:197-209.
28. Masdeu JC, Zubieta JL, Arbizu J. Neuroimaging as a marker of the onset and progression of Alzheimer's disease. J Neurol Sci 2005.
29. Chetelat G, Eustache F, Viader F. FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment. Neurocase 2005;11:14-25.
30. Jagust W, Thisted R, Devous MD, Sr. SPECT perfusion imaging in the diagnosis of Alzheimer's disease: a clinical-pathologic study. Neurology 2001;56:950-6.
31. Reiman EM, Chen K, Alexander GE. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A 2004;101:284-9.
32. Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry 2002;159:738-45.
33. Shoghi-Jadid K, Small GW, Agdeppa ED. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 2002;10:24-35.
34. Klunk WE, Engler H, Nordberg A. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-19.
35. Josephs KA, Petersen RC, Knopman DS. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology 2006;66:41-8.
36. Franceschi M, Anchisi D, Pelati O. Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration. Ann Neurol 2005;57:216-25.
37. García-Garzón JR, Simo-Perdigo M, González- González JM, Pérez-Moure G, López-Gandul S, Lomena-Caballero F. Early diagnosis of primary progressive aphasia by positron emission tomography. Rev Neurol 2005;40:572-3.
38. Jeong Y, Park KC, Cho SS. Pattern of glucose hypometabolism in frontotemporal dementia with motor neuron disease. Neurology 2005;64:734-6.
39. Minoshima S, Foster NL, Sima AA, Frey KA, Albin RL, Kuhl DE. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol 2001;50:358-65.
40. Tohgi H, Yonezawa H, Takahashi S. Cerebral blood flow and oxygen metabolism in senile dementia of Alzheimer's type and vascular dementia with deep white matter changes. Neuroradiology 1998;40:131-7.
41. Antonini A, Kazumata K, Feigin A. Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET. Mov Disord 1998;13:268-74.
42. Juh R, Kim J, Moon D, Choe B, Suh T. Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET. Eur J Radiol 2004;51:223-33.
43. Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ. Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:968-75.